Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07864272
Recruiting Observational

Assessment of Invasive Genetic Testing in Fetuses With Isolated Intrauterine Growth Restriction Diagnosed After 28 Weeks of Gestation at Strasbourg University Hospitals (2016-2023)

NCT07864272 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2026-01-12
Last updated
2026-10-07

Condition(s) studied

Isolated Intrauterine Growth Restriction (IUGR)

Study summary

This study evaluates the diagnostic yield of invasive genetic testing in fetuses with isolated intrauterine growth restriction diagnosed after 28 weeks of gestation, in order to better define indications for invasive procedures and improve clinical counseling.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Maternal age ≥ 18 years * Referral after 28 weeks of gestation for estimated fetal weight \< 3rd percentile, isolated condition * Management at Strasbourg University Hospitals between 01/01/2016 and 01/01/2023 * No documented opposition to reuse of medical data for research Exclusion Criteria: * Suspected fetal structural anomaly or infectious cause * Multiple pregnancy * Incomplete genetic workup

Primary outcome measure(s)

  • Diagnostic yield of invasive genetic testing in isolated IUGR — 2016-2023 retrospective period
    Proportion of invasive prenatal procedures identifying a genetic abnormality explaining the intrauterine growth restriction

Trial sites (1)

FacilityCityRegionStatus
Service de Gynécologie et Obstétrique - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864272 on ClinicalTrials.gov ↗ ← All trials in France